CLAIMS

1. Use of a peptide of 14 amino acids having the sequence ID No. 1
or a peptide of up to 16 amino acids having a sequence with at least 85%, preferably at least 90%, and preferably at least 95% identity with sequence ID No. 1,
or a derivative and/or salt thereof**,**
in the manufacture of a medicament for the treatment and/or prevention of skin dyschromia and/or de-innervation diseases of the skin,
wherein said derivative includes an N and/or a C terminal of said peptide which is chemically modified or protected with an organic compound.

2. The use according to claim 1, wherein the peptide has a sequence with at least 85%, preferably at least 90%, and preferably at least 95% identity with the sequence ID No. 1, wherein said peptide has a length of up to 15 amino acids, more preferably of 14 amino acids.

3. The use according to claim 1 or 2, wherein said compound is selected from the group consisting of phosphoryl, glycosyl, acyl, alkyl, carboxyl, hydroxyl, biotinyl, ubiquitinyl, and amide.

4. Use of a pharmaceutical composition consisting of
a peptide of 14 amino acids having the sequence ID No. 1,
or a peptide of up to 16 amino acids having a sequence with at least 85%, preferably at least 90%, and preferably at least 95% identity with sequence ID No. 1,
or a derivative and/or salt thereof,
and at least one pharmaceutically acceptable excipient,
in the manufacture of a medicament for the treatment and/or prevention of skin dyschromia and/or de-innervation diseases of the skin,
wherein said derivative includes an N and/or a C terminal of said peptide which is chemically modified or protected with an organic compound.

5. The use according to claim 4, said composition comprising from 10 to 10,000 µg/mL, preferably from 100 to 5,000 µg/mL, and more preferably from 200 to 4,000 µg/mL of said peptide.

6. The use according to claim 4 or 5, said composition is to be topically administered, preferably in the form of lotion, cream, gel, stick, spray, ointment, paste, mousse.

7. The use according to any one of claims 4 to 6 wherein said at least one pharmaceutical acceptable excipient is selected from the group consisting of pharmaceutically acceptable vehicles, volatile and non-volatile solvents, water, surfactants, preservatives, absorbents, chelators, lubricants, moisturisers, water repellents, antioxidants, UV absorbers, anti-irritants, vitamins, trace metals, antimicrobial agents, perfumes, dyes and colored ingredients and/or structuring agents.

8. The use according to any one of claims 1 to 7 wherein said skin dyschromia is selected from: vitiligo, bilateral vitiligo, acrofacial vitiligo, generalized vitiligo, focal vitiligo, segmental vitiligo, universal vitiligo, perinevic or Sutton's nevus vitiligo, leukoderma, piebaldism, pityriasis alba, pityriasis versicolor, idiopathic and post-inflammatory guttata hypomelanosis, acromic or depigmented nevi, progressive macular hypomelanosis, hypomelanosis caused by metabolic or nutritional or endocrine disorders, hypomelanosis caused by chemical, physical or pharmaceutical agents, infectious and post-infectious hypomelanosis, inflammatory edipomelanosis.

9. The use according to claim 8, wherein the peptide or composition is to be administered in combination with a steroid-based or calcitriol-based compound or composition.

10. The use according to any one of claims 1 to 7 wherein said de-innervation disease of the skin is selected from: trigeminal trophic syndrome, post-herpes zoster itching, dysesthesia of the scalp, parestetic notalgia, brachioradial itching, parestetic meralgia, itching associated with keloids or burn scars, neuropathy of small fibers in the course of systemic diseases.

11. The use according to claim 10, wherein the peptide or composition is to be administered in combination with an antiviral compound or composition.